The effect of therapy with the drug Mexol on the regression of neurological deficiency and a functional outcome in patients with ischemic stroke: a systematic review and meta analysis

Authors:
I.A. Voznyuk ^1.2 , S.V. Kolomensev ^2.3 , E.M. Morozova ¹

¹ FSBEI in "First St. Petersburg State Medical University named after I.P. Pavlova "of the Ministry of Health of Russia, St. Petersburg, Russia;
² Baltic Center for Neurotechnology and Artificial Intelligence FGAOU in Baltic Federal University named after Immanuel Kant ”, Kaliningrad, Russia;
³ FSBVOU in the "Military Medical Academy named after CM. Kirova »Ministry of Defense of Russia, St. Petersburg, Russia

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2023, T. 123, No. 12, Issue. 2

Summary:
Purpose of the study. A systematic assessment of information published in the reviewed publications on the effect of therapy with Mexidol with the course and outcome of ischemic stroke (AI) in adult patients.

Material and methods. The meta-analysis includes 11 studies published in Russian (2-randomized controlled, 9-incomeized unraveling cohort studies).

Results. Data was obtained indicating the positive effect of Mexol's drug on the course of AI in adult patients: statistically significant, when comparing with the comparison group, a decrease in the NIHSS scale on the 7-10s and 21-24 days and the values ​​of the modified Rankin scale by 5- 7th and 10-14th day. The accumulative effect of the drug is shown: the difference in values ​​on the NIHSS scale grows as the observation duration increases. The effect of Mexidol’s influence on the indicators on the NIHSS scale is all the more significant, the greater the initial severity of the neurological deficit.

Conclusion. The heterogeneity of the design and characteristics of patients led to significant statistical heterogeneity, and therefore the evidence presented at the time of writing the review require further study, taking into account the emergence of new data.

Keywords: ischemic stroke, neuroprotection, Mexidol, ethyl-methylhydroxypyridine succinate, meta-analysis, NIHSS scale, modified Rankin scale, cerebrovascular diseases.